Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
UKALL XI (92) - Acute lymphoblastic leukaemia trial
ISRCTN ISRCTN16757172
DOI 10.1186/ISRCTN16757172
ClinicalTrials.gov identifier
EudraCT number
Public title UKALL XI (92) - Acute lymphoblastic leukaemia trial
Scientific title
Acronym UKALL XI (92)
Serial number at source G8223452
Study hypothesis To test if CNS disease eradication can be successfully achieved without cranial radiotherapy by using CNS directed chemotherapy, to determine whether the use of high-dose intravenous MTX as part of the CNS therapy will reduce the incidence of systematic relapse, to assess whether a third intensification block of chemotherapy effects disease free survival, to compare by psychometric testing the long term learning and neuropsychological effects of the different CNS treatments.

Please note that the target number of participants was added as of 18/07/2007.
Lay summary
Ethics approval Not provided at time of registration.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Leukaemia
Participants - inclusion criteria They are children including those with Down's syndrome or leukaemia associated chromosome translocations over 1 year and under 15 years with newly diagnosed ALL of any immunologic subtype except B-ALL
Participants - exclusion criteria Children with B-ALL and those under 1 year
Anticipated start date 01/01/1990
Anticipated end date 31/12/1997
Status of trial Completed
Patient information material
Target number of participants 2,090 children were recruited
Interventions Central Nervous System (CNS) directed chemotherapy/control
Primary outcome measure(s) Disease-free survival, CNS disease eradication, relapse rates, psychometric test results.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (UK)
Trial website
Publications Results:
1. http://www.ncbi.nlm.nih.gov/pubmed/11328289
2. http://www.ncbi.nlm.nih.gov/pubmed/14675406
3. http://www.ncbi.nlm.nih.gov/pubmed/11813173
Contact name Dr  F  Hill
  Address The Children's Hospital
Ladywood Middleway
  City/town Birmingham
  Zip/Postcode B16 8ET
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 25/10/2000
Last edited 31/03/2009
Date ISRCTN assigned 25/10/2000
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.